Ela Mijatovic, Kelly Ascenção, Csaba Szabo, Tomas Majtan
{"title":"Cellular turnover and degradation of the most common missense cystathionine beta-synthase variants causing homocystinuria.","authors":"Ela Mijatovic, Kelly Ascenção, Csaba Szabo, Tomas Majtan","doi":"10.1002/pro.5123","DOIUrl":null,"url":null,"abstract":"<p><p>Homocystinuria (HCU) due to cystathionine beta-synthase (CBS) deficiency is the most common inborn error of sulfur amino acid metabolism. Recent work suggests that missense pathogenic mutations-regardless of their topology-cause instability of the C-terminal regulatory domain, which likely translates into CBS misfolding, impaired assembly, and loss of function. However, it is unknown how instability of the regulatory domain translates into cellular CBS turnover and which degradation pathways are involved in CBS proteostasis. Here, we developed a human HEK293-based cellular model lacking intrinsic CBS and stably overexpressing wild-type (WT) CBS or its 10 most common missense HCU mutants. We found that HCU mutants, except the I278T variant, expressed similarly or better than CBS WT, with some of them showing impaired oligomerization, activity and response to allosteric activator S-adenosylmethionine. Cellular stability of all HCU mutants, except P49L and A114V, was significantly lower than the stability of CBS WT, suggesting their increased degradation. Ubiquitination analysis of CBS WT and two representative CBS mutants (T191M and I278T) showed that proteasomal degradation is the major pathway for CBS disposal, with a minor involvement of lysosomal-autophagic and endoplasmic reticulum-associated degradation (ERAD) pathways for HCU mutants. Proteasomal inhibition significantly increased the half-life and activity of T191M and I278T CBS mutants. Lysosomal and ERAD inhibition had only a minor impact on CBS turnover, but ERAD inhibition rescued the activity of T191M and I278T CBS mutants similarly as proteasomal inhibition. In conclusion, the present study provides new insights into proteostasis of CBS in HCU.</p>","PeriodicalId":20761,"journal":{"name":"Protein Science","volume":"33 8","pages":"e5123"},"PeriodicalIF":4.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264351/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Protein Science","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1002/pro.5123","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Homocystinuria (HCU) due to cystathionine beta-synthase (CBS) deficiency is the most common inborn error of sulfur amino acid metabolism. Recent work suggests that missense pathogenic mutations-regardless of their topology-cause instability of the C-terminal regulatory domain, which likely translates into CBS misfolding, impaired assembly, and loss of function. However, it is unknown how instability of the regulatory domain translates into cellular CBS turnover and which degradation pathways are involved in CBS proteostasis. Here, we developed a human HEK293-based cellular model lacking intrinsic CBS and stably overexpressing wild-type (WT) CBS or its 10 most common missense HCU mutants. We found that HCU mutants, except the I278T variant, expressed similarly or better than CBS WT, with some of them showing impaired oligomerization, activity and response to allosteric activator S-adenosylmethionine. Cellular stability of all HCU mutants, except P49L and A114V, was significantly lower than the stability of CBS WT, suggesting their increased degradation. Ubiquitination analysis of CBS WT and two representative CBS mutants (T191M and I278T) showed that proteasomal degradation is the major pathway for CBS disposal, with a minor involvement of lysosomal-autophagic and endoplasmic reticulum-associated degradation (ERAD) pathways for HCU mutants. Proteasomal inhibition significantly increased the half-life and activity of T191M and I278T CBS mutants. Lysosomal and ERAD inhibition had only a minor impact on CBS turnover, but ERAD inhibition rescued the activity of T191M and I278T CBS mutants similarly as proteasomal inhibition. In conclusion, the present study provides new insights into proteostasis of CBS in HCU.
胱硫醚-β-合成酶(CBS)缺乏导致的高胱氨酸尿症(HCU)是硫氨基酸代谢中最常见的先天性错误。最近的研究表明,错义致病突变--无论其拓扑结构如何--都会导致 C 端调节结构域的不稳定,从而可能转化为 CBS 的错误折叠、组装受损和功能丧失。然而,调节结构域的不稳定性如何转化为细胞 CBS 的更替,以及哪些降解途径参与了 CBS 蛋白稳态,目前尚不清楚。在这里,我们建立了一个基于 HEK293 的人类细胞模型,该模型缺乏内在 CBS,并稳定地过表达野生型(WT)CBS 或其 10 个最常见的错义 HCU 突变体。我们发现,除 I278T 突变体外,HCU 突变体的表达与 CBS WT 相似或更好,但其中一些突变体的寡聚化、活性和对异位激活剂 S-腺苷蛋氨酸的反应受到损害。除 P49L 和 A114V 外,所有 HCU 突变体的细胞稳定性都明显低于 CBS WT,这表明它们的降解增加了。对 CBS WT 和两个具有代表性的 CBS 突变体(T191M 和 I278T)的泛素化分析表明,蛋白酶体降解是 CBS 降解的主要途径,HCU 突变体的溶酶体-自噬和内质网相关降解(ERAD)途径参与较少。蛋白酶体抑制能显著提高 T191M 和 I278T CBS 突变体的半衰期和活性。溶酶体和ERAD抑制对CBS的周转只有轻微影响,但ERAD抑制与蛋白酶体抑制同样能挽救T191M和I278T CBS突变体的活性。总之,本研究为了解 HCU 中 CBS 的蛋白稳态提供了新的视角。
期刊介绍:
Protein Science, the flagship journal of The Protein Society, is a publication that focuses on advancing fundamental knowledge in the field of protein molecules. The journal welcomes original reports and review articles that contribute to our understanding of protein function, structure, folding, design, and evolution.
Additionally, Protein Science encourages papers that explore the applications of protein science in various areas such as therapeutics, protein-based biomaterials, bionanotechnology, synthetic biology, and bioelectronics.
The journal accepts manuscript submissions in any suitable format for review, with the requirement of converting the manuscript to journal-style format only upon acceptance for publication.
Protein Science is indexed and abstracted in numerous databases, including the Agricultural & Environmental Science Database (ProQuest), Biological Science Database (ProQuest), CAS: Chemical Abstracts Service (ACS), Embase (Elsevier), Health & Medical Collection (ProQuest), Health Research Premium Collection (ProQuest), Materials Science & Engineering Database (ProQuest), MEDLINE/PubMed (NLM), Natural Science Collection (ProQuest), and SciTech Premium Collection (ProQuest).